Study on Off-Label Antidepressant Prescriptions

Overview of the Research

A study published in the British Medical Journal investigated the prevalence and scientific backing for off-label antidepressant prescriptions. The researchers concluded that these prescriptions typically lack strong scientific evidence and emphasized the need for generating and providing physicians with such evidence to enhance prescribing practices.

Antidepressants and Their Uses

Antidepressant medications are frequently prescribed to treat depressive disorders as well as various other conditions, including anxiety, eating disorders, sleep disorders, chronic pain, and obsessive-compulsive disorder. In recent years, the prescription rates for antidepressants have risen in the United States, Canada, and the UK. Notably, in England, antidepressant prescriptions increased by approximately 3.9 million, or 7%, between 2014 and 2015. This rise is partly attributed to the growing range of conditions for which antidepressants are utilized, many of which are classified as “off-label.” In medical terms, an “indication” refers to a reason for using a medication. It is estimated that around 29% of antidepressants are prescribed for off-label indications.

Risks of Off-Label Drug Use

Off-label drug use is often associated with an increased risk of adverse events when not supported by robust scientific evidence. Therefore, it is crucial to better understand the scientific backing for off-label antidepressant indications.

Study Methodology

The authors conducted a descriptive study in primary care practices across two cities in Quebec, Canada, to investigate off-label indications and assess the level of scientific support for these prescriptions. Primary care physicians in the study utilized an electronic prescribing system, collecting information from patients aged 18 and older who were prescribed antidepressants from 2003 to 2015. In total, 106,850 prescriptions were analyzed for 20,920 adults by 174 physicians.

Findings on Off-Label Prescriptions

The researchers measured the prevalence of off-label prescriptions by drug and class. They categorized the off-label antidepressant prescriptions into three groups:
1. Strong evidence supporting the use of the prescribed drug for the respective indication.
2. No strong evidence for the prescribed drug, but strong evidence supporting the use of another drug in the same class for the indication.
3. No strong evidence supporting the use of the prescribed drug or any others in the same class for the indication.

In terms of drug class, tricyclic antidepressants were the most frequently prescribed for off-label uses. Notably, Trazodone accounted for 26% of off-label prescriptions due to its use for insomnia. The study found that only 16% of off-label prescriptions were backed by strong scientific evidence. In contrast, in 44% of cases, there was no evidence supporting the prescribed drug or any other in its class for the specific indication.

Conclusions and Recommendations

The authors concluded that off-label antidepressant prescriptions frequently lack the necessary scientific support for their respective indications. However, there is often supporting evidence for alternative drugs within the same class that could be utilized. To improve prescribing practices, further research on the clinical outcomes of off-label use is essential. Additionally, indication-based electronic prescribing systems represent valuable resources for studying off-label uses and providing relevant information to physicians.

Written By: Katherine M. Evely, MS